Form 4 for XFOR X4 Pharmaceuticals, Inc
Accepted 2022-08-19 00:00:00 ET · period of report 2022-08-17 · accession 0001628280-22-023324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-19 | 2022-08-17 | XFOR | Ragan Paula | Pres, CEO, Dir | S - Sale | — | -13.4K | 634.9K | -2% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-17 | S | D | 13,448 | — | 634,910 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.155 to $1.220, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F2) Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award (F4) Of the shares of common stock reported, 361,079 shares represent unvested restricted stock units. |